Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Celldex Therapeutics Inc (NASDAQ: CLDX) was $20.14 for the day, down -4.87% from the previous closing price of $21.17. In other words, the price has decreased by -$4.87 from its previous closing price. On the day, 0.51 million shares were traded. CLDX stock price reached its highest trading level at $21.53 during the session, while it also had its lowest trading level at $19.97.
Ratios:
Our analysis of CLDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 18.91 and its Current Ratio is at 18.91. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on February 13, 2025, initiated with a Buy rating and assigned the stock a target price of $44.
On October 07, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $70.
On September 30, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $45.Goldman initiated its Neutral rating on September 30, 2024, with a $45 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 11 ’24 when Marucci Anthony S bought 11,500 shares for $26.82 per share. The transaction valued at 308,430 led to the insider holds 40,284 shares of the business.
Martin Samuel Bates sold 17,172 shares of CLDX for $608,315 on Jun 14 ’24. The SVP AND CFO now owns 28,125 shares after completing the transaction at $35.42 per share. On Jun 14 ’24, another insider, Crowley Elizabeth, who serves as the SR. VP & CPDO of the company, sold 30,000 shares for $34.87 each. As a result, the insider received 1,045,962 and left with 9,074 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1336969728 and an Enterprise Value of 615501952. For the stock, the TTM Price-to-Sale (P/S) ratio is 190.45 while its Price-to-Book (P/B) ratio in mrq is 1.79. Its current Enterprise Value per Revenue stands at 87.678 whereas that against EBITDA is -3.207.
Stock Price History:
The Beta on a monthly basis for CLDX is 1.51, which has changed by -0.5205903 over the last 52 weeks, in comparison to a change of 0.07903516 over the same period for the S&P500. Over the past 52 weeks, CLDX has reached a high of $47.50, while it has fallen to a 52-week low of $18.61. The 50-Day Moving Average of the stock is -12.61%, while the 200-Day Moving Average is calculated to be -34.22%.
Shares Statistics:
CLDX traded an average of 895.25K shares per day over the past three months and 870060 shares per day over the past ten days. A total of 66.37M shares are outstanding, with a floating share count of 64.70M. Insiders hold about 2.54% of the company’s shares, while institutions hold 109.67% stake in the company. Shares short for CLDX as of 1740700800 were 8875878 with a Short Ratio of 9.91, compared to 1738281600 on 8873582. Therefore, it implies a Short% of Shares Outstanding of 8875878 and a Short% of Float of 15.459999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
